Skip to content

Treatment of knee Osteoarthritis with Bone Marrow Aspirate Concentrate

Treatment of Knee Osteoarthritis with Bone Marrow Aspirate Concentrate: Prospective Randomized Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-7rk9hn7
Enrollment
Unknown
Registered
2025-09-23
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other primary knee osteoarthritis

Interventions

This study is a prospective, randomized clinical trial aimed at evaluating the effects of using bone marrow aspirate and concentrated bone marrow aspirate compared to the bone marrow aspirate matrix (

Sponsors

Faculdade de Medicina da Universidade Federal Fluminense
Lead Sponsor
Hospital Universitário Antonio Pedro/Empresa Brasileira de Serviços Hospitalares
Collaborator

Eligibility

Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age between 50 and 70 years old; both sexes; diagnosis of Bilateral Osteoarthritis of the knee, according to the criteria of the American College of Rheumatology; radiographs with a Kellgren-Lawrence classification higher than III in both knees; present full range of motion (0 to 120°)

Exclusion criteria

Exclusion criteria: History of previous trauma, infection or surgery in the same knee in the last 2 years;limb malalignment (varus>10º and valgus > 15º);corticosteroid infiltration in the same knee in the last 3 months;hyaluronic acid ; unfiltration in the same knee in the last 12 months;inflammatory, autoimmune or neoplasic disease;body mass index> 35 kg/m2; use of immunosuppressants or anticoagulants; active neoplasia; hematologic disorders; history of transmissible disease accute or chronic; living outside Rio de Janeiro metropolitan area; participants without full autonomy, blind, deaf or illiterate; patients unable for positioning; patients using statins

Design outcomes

Primary

MeasureTime frame
A 1.5 difference in pain analysed by visual analog scale is expected.

Secondary

MeasureTime frame
An improvement of 20% in function analysed by WOMAC (Western Ontario and McMaster Univesities Osteoarthritis Index) and KSS (Knee Society Score) is expected.

Countries

Brazil

Contacts

Public ContactEduardo de Sousa

Universidade Federal Fluminense

eduardobranco@id.uff.br+55-21-972388005

Outcome results

None listed

Source: REBEC (via WHO ICTRP)